Neurocrine Biosciences
NBIX
#1273
Rank
NZ$30.90 B
Marketcap
NZ$307.32
Share price
-1.91%
Change (1 day)
38.47%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2026 (TTM): NZ$1.36 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are NZ$3.10 Billion. In 2025 the company made an earning of NZ$1.10 Billion, an increase over its 2024 earnings that were of NZ$1.06 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.36 B23.91%
2025 NZ$1.10 B3.9%
2024 NZ$1.06 B96.41%
2023 NZ$0.54 B41.13%
2022 NZ$0.38 B73.74%
2021 NZ$0.22 B-8.82%
2020 NZ$0.24 B77.78%
2019 NZ$0.13 B49.83%
2018 NZ$90.87 M-142.57%
2017 -NZ$0.22 Billion-14.73%
2016 -NZ$0.26 Billion53.15%
2015 -NZ$0.17 Billion46.25%
2014 -NZ$0.12 Billion29.66%
2013 -NZ$86.21 Million-3530.8%
2012 NZ$2.51 M-95.73%
2011 NZ$58.86 M
2009 -NZ$82.75 Million-45.38%
2008 -NZ$0.16 Billion-58.87%
2007 -NZ$0.37 Billion87.3%
2006 -NZ$0.2 Billion351.97%
2005 -NZ$43.51 Million-52.09%
2004 -NZ$90.81 Million-10.98%
2003 -NZ$0.11 Billion
2001 -NZ$76.15 Million
1999 -NZ$34.34 Million108.32%
1998 -NZ$16.49 Million
1996 NZ$5.03 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$18.37 B 1,225.86%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$11.44 B 725.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$54.00 B 3,796.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$0.14 B-89.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-NZ$72.47 Million-105.23%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$0.16 B-88.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-NZ$8.33 Million-100.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.94 B 112.21%๐Ÿ‡ฌ๐Ÿ‡ง UK